Efficacy of Quadrivalent Inactivated Influenza Vaccine

doi:10.1542/gr.31-4-41

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Download PDF

Source: Jain VK, Rivera L, Zaman K, et al. Vaccine for prevention of mild and moderate-to-severe influenza in children. N Engl J Med. 2013; 369( 26): 2481– 2491; doi: 10.1056/NEJMoa1215817OpenUrl CrossRef PubMed

PICO

Question: Among children ages 3 to 8 years, what is the efficacy of the new quadrivalent inactivated influenza vaccine in preventing mild and moderate-to-severe influenza?

Question type: Intervention

Study design: Randomized controlled

Investigators from 15 centers in 8 countries sought to evaluate the efficacy of a candidate quadrivalent inactivated influenza vaccine (QIV) containing the A/H1N1, A/H3N2, B/Victoria, and B/Yamagata strains. Healthy children 3 to 8 years of age were randomly assigned, in a 1:1 ratio, to receive QIV (1 or 2 doses depending on their vaccine priming status) or hepatitis A vaccine as a control. Both vaccines were manufactured by GlaxoSmithKline Biologicals, the sponsor of this clinical trial.

Enrollment began in December 2010. Active and passive surveillance for influenza-like illness (ILI) – defined as a temperature …

View Full Text